Generex Biotech Corp

http://www.nasdaq.com/earnings/...ame=&page=analystinfo&selected=GNBT  

und der Steuerfreibetrag ist doch schon lange eingeloggt.
Das war ne gute Woche!  

es geht nach oben :-)

Wär schön wenn wir mit >= 4US$ ins Wochenende gehen würden ;-)  

Generex Biotechnology Announces Successful Equipment & Filling Line Installation for Commencement of Generex Oral-Lyn(TM) Commercial Production


Company Also Comments on Factual Inaccuracies in Story on Internet Site


TORONTO -- (MARKET WIRE) -- 03/27/06 -- Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, today announced the successful completion of the delivery and installation of a turnkey Generex Oral-lyn(TM) filling operation at the facilities of PharmaBrand, S.A. (www.pharmabrand.com.ec) in Quito, Ecuador. PharmaBrand is the Company's joint venture partner for the commercialization of Generex Oral-lyn in Latin America. Generex Oral-lyn is the Company's proprietary oral insulin spray product which is designed to replace prandial subcutaneous injections of insulin by delivering insulin into the human body via a spray applied to the buccal mucosa using the Company's proprietary RapidMist(TM) device.

A regulatory compliance and quality control team from Generex will attend at the PharmaBrand facilities early next month to assist in the training of PharmaBrand personnel in respect of the operation of the filling equipment. The Company anticipates that the first commercial production run of 50,000 canisters of Generex Oral-lyn will be completed in April, 2006. Prior to the commencement of that production run, PharmaBrand will have completed the training of its sales force in respect of the new diabetes treatment paradigm offered by Generex Oral-lyn's safe, simple, fast, effective, familiar, and pain-free alternative to prandial insulin injections for patients with either Type-1 or Type-2 diabetes.

The Generex team will also undertake an evaluation of the PharmaBrand manufacturing facilities with a view to assessing the prospect of utilizing those facilities for the production of proteins and peptides to support ongoing research and development in respect of the Antigen Express immunotherapeutic vaccines program.

The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuracies. The article referred to the Company's "financial struggles." As indicated in the Company's Form 10-Q Quarterly Report for the fiscal quarter ended January 31, 2006, Generex had cash and short-term investments in excess of $21 million as of January 31, 2006. As at the close of business on March 24, 2006, the Company had cash and short-term investments in excess of $41 million, the strongest financial condition in the Company's history.

The article states that "for the past year, Generex hasn't been able to pay off its debt." That statement is false.

The article states that Generex failed to repay two promissory notes and that "[a]s a result the noteholders (sic) were allowed to convert the debt" into shares of common stock. That statement is false. Had the author reviewed the terms of the debt, he would have seen that the conversion entitlements were included in the promissory notes from the outset. The promissory notes were not repaid in cash on the maturity dates in the context of then on-going negotiations in respect of related transactions. The author states that "Generex also agreed to such terms with other lenders." That is another false statement.

The author makes derisive reference to the Company's losses. Generex is a development stage biotechnology corporation; accordingly, its function has been to spend money on research and development activities which expenditures are recorded as losses. He fails to mention that all of the other small biotechnology companies in the article incurred substantial losses for similar reasons. The author is correct, however, when he makes reference to the Company's expectation of receiving revenue from the sale of Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, by August, 2006.

The author states that Generex is "a stock that faces the threat of delisting." That statement is false. On November 15, 2005, the Company announced that it had received written confirmation from the Nasdaq Stock Market that the Company had achieved compliance with the continued listing requirements in accordance with Nasdaq Marketplace Rule 4310(c)(4). At the present time, Generex very comfortably meets all of the Nasdaq Stock Market quantitative continued listing requirements.

The article is correct when it states that the Antigen Express avian flu vaccine is in pre-clinical development (following a pre-IND meeting with the FDA on February 10, 2006) and that the Antigen Express breast cancer vaccine is in Phase 1 human clinical trials (at Walter Reed Army Medical Center).

"We do not seek to discourage critical review; however, we consider that such review should be based on accurate facts," stated Anna Gluskin, Generex's President & Chief Executive Officer. "The Company made its executives available for the author to speak with. Unfortunately, whatever his underlying motives were, he chose to misstate and distort the facts thereby portraying the Company in an unjustifiably negative manner."

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

 

 

ließ mal genauer! Da scheinen ziehmlich falsche Gerüchte gestreut worden zu sein :-(
Irgendwie will sie aber auch auf die Richtigstellung nicht reagieren. Ich habe heute nochmal nachgekauft, denn der Beginn der Oral Lyn Vermarktung ist eigentlich schon sehr positiv zu werten. Ich hoffe sie erholt sich noch bis Handelsende.  

Hot Stocks Investor - Generex Biotechnology einsteigen  

12:06 28.03.06  

Die Experten von "Hot Stocks Investor" empfehlen bei der Aktie von Generex Biotechnology (ISIN US3714851033/ WKN 922012) die Turbulenzen nach der Überhitzung der ersten Kursrally zu einem Einstieg zu nutzen.

Das Unternehmen werde zwar derzeit immer wieder im Zusammenhang mit Impfstoff-Forschungen genannt, der eigentliche Schwerpunkt liege aber im Bereich der Diabetes. Mit ORAL-LYN habe das Unternehmen ein Präparat in der Entwicklung, welches besonders spannendes Potenzial aufweisen sollte. Das Diabetes-Präparat könne nämlich oral via Inhalator aufgenommen werden.

Gemäß den Zahlen der "International Diabetes Federation" würden im Jahre 2025 weltweit 333 Mio. Diabetiker prognostiziert. Der neue Diabetes-Atlas weise eine Zahl von 314 Mio. Menschen aus, welche ein Risiko hätten, an Diabetes mellitus zu erkranken. Während z. B. 1960 nur 0,6 Prozent der Deutschen an Diabetes gelitten hätten, seien es im Jahr 2005 rund 10 Prozent gewesen. Derzeit würden 6,3 Mio. Menschen in Deutschland an Diabetes leiden und Experten würden davon ausgehen, dass die Zahl im Jahre 2010 auf 10 Mio. anwachsen werde. Bei aktuellen Behandlungskosten von 5.000 EUR p. a. lasse sich ermessen, über was für ein weltweites Marktpotenzial hier zu sprechen sei.

Auch wenn Generex den endgültigen Durchbruch noch liefern müsse, habe man doch schon erste sehr viel versprechende Teilerfolge geliefert. So sei in der vergangenen Woche die Zulassung des Wirkstoffs für die Indikation Diabetes Typ eins und zwei in Ecuador verkünden können. Mit Eli Lilly sei einer der weltgrößten Pharmakonzerne bei dem Projekt bereits mit im Boot.

Die Experten von "Hot Stocks Investor" raten bei der Generex Biotechnology-Aktie die Turbulenzen nach der Überhitzung der ersten Kursrally zu einem Einstieg zu nutzen.

http://www.ariva.de/news/article.m?id=2053707&secu=6215  

Gestern bei 3,16 USD geschlossen, heute:

Last Price  
3.16  
Change $
 
Change %
 
Tick
   

Bid 3.29   Bid Size 5000  
Ask 3.30   Ask Size 5200  
Open N/A   High N/A   Low N/A  
Prev Close 3.16  

Last Trade 3/28/06  
Volume  0  
52 Wk Hi 4.49   52 Wk Lo 0.51  

Market Cap 281.16 m  
Ex-Div Date N/A  
Dividend N/A  
Yield N/A  

Shares 88.97 m  
EPS (TTM) -0.73  
PE Ratio N/A  
Exchange NSD  

Bals sind wir alle reich... Steinreich.

lg
o
 

 

 

Naja, bis jetzt ging da wohl eher weniger... Bin auch am 29.03. zu 2,69 € eingestiegen und überrascht, daß die so wegsackt. Charttechnisch sieht´s aber jetzt schon wieder besser aus, die Indikatoren nähern sich dem überverkauften Bereich. Der USA Chart setzt fast von oben auf die Mittellinie der Bollinger Bands auf, der erweist sich oft als Unterstützung, also sollte es möglichst nicht unter 3,-$ gehen. Bei ca. 2,50 $ wartet unter anderem die 38-Tage Linie als Unterstützung. Darunter kommt dann ´ne ganze Weile nichts mehr... Im Tageschart hat die 3-Dollar-Marke gehalten, also hoffen wir das auch für nächste Woche, dann könnte es wieder nach oben gehen!
Was mich echt irritiert sind die Wahnsinnsumsätze in USA, Tagesvolumen 27,3 Mio. Dollar; 9,1 Mio. gehandelte Aktien. War gestern dasselbe. Oder habe ich da falsche Zahlen? In Frankfurt dagegen schlappe 150.000 € umgesetzt...  

ließ Dir mal die News aus #79 genauer durch!

Speziell ab 'The Company also responded to a story which appeared on an Internet site Friday afternoon that contained factual inaccuracies....'

Es wurden scheinbar Gerüchte gestreut die das Anlegervertrauen erschüttert haben! Dummerweise geht die Gegendarstellung in der AdHoc etwas unter und es wäre sicher besser gewesen, die Gegendarstellung in einer eigenen Meldung zu veröffentlichen ;-(

Ich bin überzeugt, da geht es sehr bald wieder aufwärts!  

geht denn das noch runter? Ist in USA ja ganz schön weggesackt. Lieber verkaufen oder jetzt nachkaufen?  

 

must come down. Jo, dat Teil war definitiv zu heiß gelaufen. Ich bin zwar vieeeel zu früh raus, allerdings dennoch mit schönem Gewinn. Langsam juckt es mich aber wieder in den Fingern ;-)

MfG schibi  

Ja, bin ich! Allerdings mit supertightem SL-Limit, falls die 2,5 USD nicht halten sollten.

MfG schibi  

als wäre der Zeitpunkt meines Einstieges kein schlechter gewesen. RT: 2,65 USD

;-) schibi  

bin auch bei 3,80 rausgegangen und hab bei 2,4  wieder gekauft hoffe war nicht zu früh
halten sich ja jetzt bei 2,2
 

möglichen Kurs von € 7-9? Das ewige rein und raus macht zumindest an der Börse nicht viel Spaß. In der Ruhe leigt die Kraft, kaufen liegen lassen und nach Weihnachten schauen was los ist, das sind gute Geschäfte!  

 

01.05.06/21:17 KGVe: -- Börse:    Nasdaq NM  

     
Berlin-Bremen  
Frankfurt  
München  
Stuttgart  
Xetra  
 
Im Ausland bewegt sich der Kurs nach Norden

3,01 USD  DIVe: 0,00 % Typ: Aktie
+13,16 %/+0,35 Jahresperf.: 209,30  
 

 

kurz erklären worum es geht?

The "death spiral convertible" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-maligned securities, whose conversion into common shares can be triggered by precipitous drops in a company's stock, all but disappeared from the market three years ago. The near extinction occurred as investors got wise to the deleterious impact an endless flood of new shares can have on price.

Subsequent allegations of manipulative trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertible. Those allegations ultimately spawned a regulatory investigation that led to a number of enforcement actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising revival in the market for death spiral convertibles -- known officially on Wall Street as "floating convertibles.''

In particular, small, cash-strapped companies with market capitalizations often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investments in public equity. The resurgence in death spiral deals may be an indication that tiny, cash-strapped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactions. By comparison, just 1.9% of all PIPE deals in 2003 were categorized as death spirals, according to research firm PlacementTracker. (PlacementTracker officially calls them floating convertibles).

Last year, death spirals accounted for 6.4% of the $20 billion-a-year PIPEs market. Death spiral deals peaked in 1999, when they represented 20% of all PIPE transactions.

Some of the companies that have done death spiral PIPE deals with floating conversion prices this past year include Generex (GNBT:Nasdaq - news - research - Cramer's Take), Vasomedical (VASO:Nasdaq - news - research - Cramer's Take) and Valence Technology (VLNC:Nasdaq - news - research - Cramer's Take), according to PlacementTracker.

he "death spiral convertible" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-maligned securities, whose conversion into common shares can be triggered by precipitous drops in a company's stock, all but disappeared from the market three years ago. The near extinction occurred as investors got wise to the deleterious impact an endless flood of new shares can have on price.

Subsequent allegations of manipulative trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertible. Those allegations ultimately spawned a regulatory investigation that led to a number of enforcement actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising revival in the market for death spiral convertibles -- known officially on Wall Street as "floating convertibles.''

In particular, small, cash-strapped companies with market capitalizations often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investments in public equity. The resurgence in death spiral deals may be an indication that tiny, cash-strapped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactions. By comparison, just 1.9% of all PIPE deals in 2003 were categorized as death spirals, according to research firm PlacementTracker. (PlacementTracker officially calls them floating convertibles).

Last year, death spirals accounted for 6.4% of the $20 billion-a-year PIPEs market. Death spiral deals peaked in 1999, when they represented 20% of all PIPE transactions.

Some of the companies that have done death spiral PIPE deals with floating conversion prices this past year include Generex (GNBT:Nasdaq - news - research - Cramer's Take), Vasomedical (VASO:Nasdaq - news - research - Cramer's Take) and Valence Technology (VLNC:Nasdaq - news - research - Cramer's Take), according to PlacementTracker.

he "death spiral convertible" might sound like your last car, but it's a bond -- and it's making an unlikely comeback on Wall Street.

These much-maligned securities, whose conversion into common shares can be triggered by precipitous drops in a company's stock, all but disappeared from the market three years ago. The near extinction occurred as investors got wise to the deleterious impact an endless flood of new shares can have on price.

Subsequent allegations of manipulative trading by some of the hedge funds that invested in these deals looked to be the death knell of the death spiral convertible. Those allegations ultimately spawned a regulatory investigation that led to a number of enforcement actions against hedge funds accused of illegally profiting from declines in stock.

Over the past year, however, there's been a surprising revival in the market for death spiral convertibles -- known officially on Wall Street as "floating convertibles.''

In particular, small, cash-strapped companies with market capitalizations often under $100 million are selling these bonds to hedge funds in deals covered by the Wall Street acronym PIPEs, or private investments in public equity. The resurgence in death spiral deals may be an indication that tiny, cash-strapped companies are finding fewer options for raising money.

This year, 10% of the 478 completed PIPE deals brought to market have been death spiral transactions. By comparison, just 1.9% of all PIPE deals in 2003 were categorized as death spirals, according to research firm PlacementTracker. (PlacementTracker officially calls them floating convertibles).

Last year, death spirals accounted for 6.4% of the $20 billion-a-year PIPEs market. Death spiral deals peaked in 1999, when they represented 20% of all PIPE transactions.

Some of the companies that have done death spiral PIPE deals with floating conversion prices this past year include Generex (GNBT:Nasdaq - news - research - Cramer's Take), Vasomedical (VASO:Nasdaq - news - research - Cramer's Take) and Valence Technology (VLNC:Nasdaq - news - research - Cramer's Take), according to PlacementTracker.

 

Hallo, das heisst im Klartext und Kurztext:
Börsennotierte Unternehmen, wie Generex, erhalten von privaten Grossanlegern (zB Hedgefunds) Geldzuflüsse. Als Gegenleistung bekommen diese Anleger Aktien des Unternehmens, jedoch wurde die Zahl der Aktien nicht festgelegt, dh. innerhalb einer bestimmten Zeit können diese Firmen den Gegenwert der Transaktion in Aktien umwandeln. Wenn zwischenzeitlich der Kurs der Aktie fällt , erhalten sie mehr Aktien für die gleiche Summe. Im Klartext üben diese Anleger durch Leerverkäufe oder andere Methoden Druck auf den Kurs aus, um so viele Aktien wie möglich zu bekommen. DER KURS FÄLLT. Sind alle Aktien an Bord, wird der Kurs gepusht um die Aktien an Kleinanleger zu höheren Kursen wieder zu verkaufen. Danach fällt der überhöhte Kurs wieder. Verlierer sind die Kleinanleger. NICHT GERADE SERIOSES VORGEHEN EINES UNTERNEHMENS .  

frei übersetzt: Todesspirale!
Velierer sind die Kleinanleger und die Hedger hauen sich auf die Schenkel. Toll!